Status:
COMPLETED
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
Lead Sponsor:
Sumitomo Pharma Co., Ltd.
Conditions:
Lung Cancer
Eligibility:
All Genders
20-74 years
Phase:
PHASE3
Brief Summary
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Eligibility Criteria
Inclusion
- Histological or cytological diagnosis of non-small cell lung cancer (NSCLC)
- 1 or 2 prior chemotherapy regimen including 1 platinum-based chemotherapy
- 20 or older but younger than 75 years of age
Exclusion
- Symptomatic brain metastasis
- Interstitial pneumonia or pulmonary fibrosis
- Abnormal cardiac function or myocardial infraction within 6 months before study enrollment
- Active infection
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT01207011
Start Date
October 1 2010
End Date
June 1 2014
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
32 Sites
Multiple Locations, Japan